APRI

Apricus Biosciences, Inc Press Releases

$1.01
*  
0.03
3.06%
Get APRI Alerts
*Delayed - data as of Dec. 24, 2014  -  Find a broker to begin trading APRI now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Apricus Biosciences Announces Year-End 2014 Update and 2015 Plans to Advance Its Clinical Pipeline and Further Commercialize Its Erectile Dysfunction Drug Vitaros(R)
12/22/2014 7:30:00 AM - GlobeNewswire


Apricus Biosciences Appoints Barbara Troupin, M.D. as Chief Medical Officer
12/15/2014 7:30:00 AM - GlobeNewswire


Apricus Biosciences Announces First Patient Enrolled in Phase 2a Clinical Trial for RayVa(TM) in Patients With Raynaud''s Phenomenon
12/4/2014 7:30:00 AM - GlobeNewswire


Apricus Biosciences Announces First Patient Enrolled in Phase 2a Clinical Trial for RayVa(TM) in Patients With Raynaud's Phenomenon
12/4/2014 7:30:00 AM - GlobeNewswire


Apricus Biosciences Appoints Brian T. Dorsey as Chief Development Officer
12/2/2014 7:30:00 AM - GlobeNewswire


Apricus Biosciences Announces Third Quarter 2014 Financial Results and Provides Corporate Update
11/10/2014 7:00:00 AM - GlobeNewswire


Apricus Biosciences to Present at Three Upcoming Investor Conferences in November and December of 2014
11/5/2014 7:30:00 AM - GlobeNewswire


Apricus Biosciences Announces Corporate Update and Third Quarter 2014 Financial Results Conference Call
11/4/2014 7:30:00 AM - GlobeNewswire


Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in Belgium by Sandoz
11/3/2014 6:00:00 AM - GlobeNewswire


Apricus Expands Development Pipeline With the In-Licensing of U.S. Rights for Fispemifene, a Phase 2b Ready Asset, From Forendo Pharma Targeting Urological Conditions in Men
10/20/2014 2:00:00 AM - GlobeNewswire


Apricus Biosciences Announces Notice of Allowance of U.S. Patent Application for RayVa(TM)
10/13/2014 7:00:00 AM - GlobeNewswire


Apricus Biosciences to Present at the 13th Annual BIO Investor Forum
10/1/2014 7:30:00 AM - GlobeNewswire